Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ABL Bio Inc. logo — A global leader in bispecific antibody therapeutics for immu...

ABL Bio Inc.

A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.

Founded 2016 Korea South Korea South 64 employees IPO Total: $49.12B Biotechnology, Health Care

General Information

Company Name ABL Bio Inc.
Founded Year 2016
Location Korea South Korea South +1
Founders / Decision Makers
Team member
Employees 64
Industries Biotechnology, Health Care
Funding Stage IPO
Social

Get notified when ABL Bio Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ABL Bio Inc.

ABL Bio Inc., founded in 2016 and headquartered in Korea South, stands as a prominent figure in the biotechnology space. Known for being a global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases, the company has carved out a niche in delivering innovative health care solutions.

Employing its proprietary platforms like ‘Grabody-T’, ‘Grabody-I’, and ‘Grabody-B’, ABL Bio has established a diverse pipeline of drug candidates targeting oncology and neurodegenerative disorders. Notably, their Grabody-T platform has shown potent efficacy in cancer treatments, whereas Grabody-B aims to revolutionize CNS drug delivery by enhancing blood-brain barrier penetration.

The company's strategic prowess is also reflected through its collaborations, highlighted by a recent $55.00M post-IPO equity investment led by Eli Lilly on 01 December 2025. This investment underscores their growth potential and commitment to pioneering medical advancements.

Taxonomy: Bispecific Antibody Therapeutics, Immuno-Oncology, Neurodegenerative Diseases, Grabody-T, Grabody-I, Grabody-B, 4-1BB Engagement, Blood-Brain Barrier Penetration, Clinical Stage Drug Candidates, Pre-Clinical Stage Drug Candidates, Antibody Drug Conjugate, CNS Targets, Strategic Partnerships, Next-Generation Antibody

Services & Products

Development of innovative therapeutic drugs
Research and development of cancer and neurodegenerative disease treatments
Creating and managing biopharmaceutical platforms
Clinical trials and regulatory approval processes

Target Customers

Healthcare providers Patients with cancer and neurodegenerative diseases Pharmaceutical companies Medical researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• 1
Investor
01 Dec 2025
IPO •••••• - 01 Dec 2018
Series C •••••• 4
Investor Investor Investor Investor
01 Jun 2018
Series B •••••• 2
Investor Investor
01 Mar 2017
Series B •••••• 1
Investor
01 Jan 2017

View All 6 Funding Rounds

ABL Bio Inc. Alternatives & Competitors

ABL Bio Inc. vs
ProfoundBio
ProfoundBio United States

An oncology biotherapeutics company

Series B
8 employees
Biotechnology, Health and Wellness
Compare ABL Bio Inc. vs ProfoundBio
ABL Bio Inc. vs
Oqory
Oqory

A clinical-stage company developing advanced antibody-drug conjugates.

ABL Bio Inc. vs
Light Chain Bioscience | Novimmune SA
Light Chain Bioscience | Novimmune SA Switzerland

Light Chain Bioscience – A brand of Novimmune SA

Series C
76 employees
Biotechnology, Pharmaceutical
Compare ABL Bio Inc. vs Light Chain Bioscience | Novimmune SA
Also compare with: ABL Bio Inc. vs Oxford BioTherapeutics Oxford BioTherapeutics ABL Bio Inc. vs CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc.

FAQ About ABL Bio Inc.

A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.
ABL Bio Inc. was founded in 2016.
ABL Bio Inc. is headquartered in Korea South.
ABL Bio Inc. operates in the following industries: Biotechnology, Health Care.
ABL Bio Inc. has approximately 64 employees.
ABL Bio Inc. has completed 6 funding rounds, raising a total of $49.12B. The latest funding stage is IPO.
ABL Bio Inc. offers: Development of innovative therapeutic drugs, Research and development of cancer and neurodegenerative disease treatments, Creating and managing biopharmaceutical platforms, Clinical trials and regulatory approval processes.
Top alternatives and competitors to ABL Bio Inc. include ProfoundBio, Oqory, Light Chain Bioscience | Novimmune SA, Oxford BioTherapeutics, Mersana Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ABL Bio Inc. and ProfoundBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ABL Bio Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes